The Lung Cancer Policy Network is a global, multidisciplinary group including clinicians, researchers, patient organisations and industry partners. Its activities and outputs are supported by its major funders Amgen, AstraZeneca, Bristol Myers Squibb Foundation, MSD, Pfizer and Siemens Healthineers; and Johnson & Johnson as a minor funder. Lilly is an arm’s‑length major funder with no influence or control over the Network or its outputs. The Health Policy Partnership, an independent health research and policy consultancy, provides the secretariat. All Network activities and outputs are non-promotional, evidence based and shaped by members, who provide their time voluntarily.